News PepGen slumps as FDA places hold on lead drug Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.
News Hansa closes on FDA verdict for transplant drug imlifidase The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.
Sales & Marketing Pharma’s search loophole is a preview of what comes next PPC ads often contain so little text that they avoid direct claims. Many consist only of a brand name, a link, and limited copy.
News New FDA knockback hits uniQure and Huntington patients hard uniQure looks like it may have to run another trial of its Huntington's disease gene therapy AMT-130, delaying the highly anticipated programme.
R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
News Moderna closes on EU approval for combined flu/COVID jab Moderna's combined vaccine for both flu and COVID-19 has been recommended for approval in the EU, after being knocked back in the US.
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
